CD19 and B-cell chronic lymphocytic leukemia: Both CAR designs proved an increased proliferation capacity and excellent cytotoxic potency of retrovirally transduced CAR-T cells [98,99].These findings promoted the application of CD19-CAR-T cells in the first successful phase I trial for treatment of chronic lymphoblastic leukemia (CLL) in 2011 [100].